Cargando…

Risk stratification in cardiogenic shock: a focus on the available evidence

Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciaccaluga, C., Mandoli, G. E., Ghionzoli, N., Anselmi, F., Dini, C. Sorini, Righini, F., Cesareo, F., D’Ascenzi, F., Focardi, M., Valente, S., Cameli, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197897/
https://www.ncbi.nlm.nih.gov/pubmed/34263413
http://dx.doi.org/10.1007/s10741-021-10140-7
_version_ 1784727514756677632
author Sciaccaluga, C.
Mandoli, G. E.
Ghionzoli, N.
Anselmi, F.
Dini, C. Sorini
Righini, F.
Cesareo, F.
D’Ascenzi, F.
Focardi, M.
Valente, S.
Cameli, M.
author_facet Sciaccaluga, C.
Mandoli, G. E.
Ghionzoli, N.
Anselmi, F.
Dini, C. Sorini
Righini, F.
Cesareo, F.
D’Ascenzi, F.
Focardi, M.
Valente, S.
Cameli, M.
author_sort Sciaccaluga, C.
collection PubMed
description Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mortality rate, that requires urgent diagnostic assessment as well as treatment; therefore, it is of paramount important to advocate for a thorough risk stratification. In fact, the early identification of patients that could benefit the most from more aggressive and invasive approaches could facilitate a more efficient resource allocation. This review attempts to critically analyse the current evidence on prognosis in cardiogenic shock, focusing in particular on clinical, laboratoristic and echocardiographic prognostic parameters. Furthermore, it focuses also on the available prognostic scores, highlighting the strengths and the possible pitfalls. Finally, it provides insights into future direction that could be followed in order to ameliorate risk stratification in this delicate subset of patients.
format Online
Article
Text
id pubmed-9197897
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-91978972022-06-16 Risk stratification in cardiogenic shock: a focus on the available evidence Sciaccaluga, C. Mandoli, G. E. Ghionzoli, N. Anselmi, F. Dini, C. Sorini Righini, F. Cesareo, F. D’Ascenzi, F. Focardi, M. Valente, S. Cameli, M. Heart Fail Rev Article Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mortality rate, that requires urgent diagnostic assessment as well as treatment; therefore, it is of paramount important to advocate for a thorough risk stratification. In fact, the early identification of patients that could benefit the most from more aggressive and invasive approaches could facilitate a more efficient resource allocation. This review attempts to critically analyse the current evidence on prognosis in cardiogenic shock, focusing in particular on clinical, laboratoristic and echocardiographic prognostic parameters. Furthermore, it focuses also on the available prognostic scores, highlighting the strengths and the possible pitfalls. Finally, it provides insights into future direction that could be followed in order to ameliorate risk stratification in this delicate subset of patients. Springer US 2021-07-14 2022 /pmc/articles/PMC9197897/ /pubmed/34263413 http://dx.doi.org/10.1007/s10741-021-10140-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sciaccaluga, C.
Mandoli, G. E.
Ghionzoli, N.
Anselmi, F.
Dini, C. Sorini
Righini, F.
Cesareo, F.
D’Ascenzi, F.
Focardi, M.
Valente, S.
Cameli, M.
Risk stratification in cardiogenic shock: a focus on the available evidence
title Risk stratification in cardiogenic shock: a focus on the available evidence
title_full Risk stratification in cardiogenic shock: a focus on the available evidence
title_fullStr Risk stratification in cardiogenic shock: a focus on the available evidence
title_full_unstemmed Risk stratification in cardiogenic shock: a focus on the available evidence
title_short Risk stratification in cardiogenic shock: a focus on the available evidence
title_sort risk stratification in cardiogenic shock: a focus on the available evidence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197897/
https://www.ncbi.nlm.nih.gov/pubmed/34263413
http://dx.doi.org/10.1007/s10741-021-10140-7
work_keys_str_mv AT sciaccalugac riskstratificationincardiogenicshockafocusontheavailableevidence
AT mandolige riskstratificationincardiogenicshockafocusontheavailableevidence
AT ghionzolin riskstratificationincardiogenicshockafocusontheavailableevidence
AT anselmif riskstratificationincardiogenicshockafocusontheavailableevidence
AT dinicsorini riskstratificationincardiogenicshockafocusontheavailableevidence
AT righinif riskstratificationincardiogenicshockafocusontheavailableevidence
AT cesareof riskstratificationincardiogenicshockafocusontheavailableevidence
AT dascenzif riskstratificationincardiogenicshockafocusontheavailableevidence
AT focardim riskstratificationincardiogenicshockafocusontheavailableevidence
AT valentes riskstratificationincardiogenicshockafocusontheavailableevidence
AT camelim riskstratificationincardiogenicshockafocusontheavailableevidence